April 15, 2015

Cicely Reese, Pharm.D.
Center for Drug Evaluation & Research
U.S. Food and Drug Administration
10903 New Hampshire Avenue, Building 31, Room 2417
Silver Spring, MD  20993-0002


Dear Dr. Reese:

On April 15, 2015, the U.S. Food and Drug Administration (FDA) published a Federal Register (FR) notice requesting notification from industry organizations interested in participating in the selection process for nonvoting industry representatives for several public advisory committees for the Center for Drug Research & Evaluation (CDER)(80 Fed. Reg. 20233-20235). Please accept this letter as an official request from the Consumer Healthcare Products Association (CHPA) to participate in the selection process. Founded in 1881, CHPA is a U.S. trade association representing manufacturers and distributors of dietary supplements and over-the-counter (OTC) drug products (http://www.chpa.org/).

CHPA would like to participate in the selection process for nonvoting industry member representation for the following FDA public advisory committees:

- Advisory Committee for Pharmaceutical Science and Clinical Pharmacology;
- Anesthetic and Analgesic Drug Products (formerly Anesthetic and Life Support Drugs);
- Arthritis Advisory Committee;
- Bone, Reproductive, and Urologic Drugs (formerly Advisory Committee for Reproductive Health Drugs);
- Dermatologic and Ophthalmic Drugs;
- Drug Safety and Risk Management;
- Gastrointestinal Drugs;
- Nonprescription Drugs; and
- Pulmonary-Allergy Drugs.
CHPA appreciates the opportunity to collaborate with the Agency and other industry organizations in selecting nonvoting industry representatives for the public advisory committees listed above. Please feel free to contact me if you have any questions.

We look forward to hearing from you about next steps.

Sincerely,

Marcia D. Howard, Ph.D.
Senior Director, Regulatory & Scientific Affairs

MDH/04-14-15